RxDoctor Payments Data

Harry Coniaris, MD

Ophthalmology · Staten Island, NYNPI 1992775563

Payments from drug & device makers

$2,111in general payments, 2019–2025

Across 54 payments — averaging $39.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$532
  • AbbVie$372
  • Sun Pharmaceutical Industries Inc.$329
  • Alcon$237
  • Bausch & Lomb Americas Inc.$225
  • Aerie Pharmaceuticals, Inc.$123
  • plus $292 from 9 others

What the payments were for

  • Food & beverage$2,111100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,111 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$577,054
Medicare patients
873
Services billed
8,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$35,941
XiidraLifitegrast16$29,593
VyzultaLatanoprostene Bunod13$8,190
LumiganBimatoprost13$7,806
Prednisolone Acetate164$5,891
SimbrinzaBrinzolamide/Brimonidine Tart17$4,603
Travoprost21$2,586
Latanoprost192$2,219
Brimonidine Tartrate47$1,484
Minocycline Hcl84$1,103
Azelastine Hcl34$1,102
Dorzolamide Hcl40$937
Ketorolac Tromethamine15$933
Diclofenac Sodium94$892
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$372$43,74639 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$225$37,78329 claims
AlconSimbrinza$237$4,60317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →